Research programme: cancer therapies - Phoremost
Alternative Names: Cancer therapies - Phoremost/PolarisQBLatest Information Update: 20 Jan 2022
At a glance
- Originator Phoremost
- Developer Phoremost; PolarisQB
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer